- Home
- LEGH vs PRME Comparison
LEGH vs PRME Comparison
Compare LEGH & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- PRME
- Stock Information
- Founded
- LEGH 2005
- PRME 2019
- Country
- LEGH United States
- PRME United States
- Employees
- LEGH N/A
- PRME N/A
- Industry
- LEGH Homebuilding
- PRME Medicinal Chemicals and Botanical Products
- Sector
- LEGH Consumer Discretionary
- PRME Health Care
- Exchange
- LEGH Nasdaq
- PRME Nasdaq
- Market Cap
- LEGH 646.4M
- PRME 693.5M
- IPO Year
- LEGH 2018
- PRME 2022
- Fundamental
- Price
- LEGH $21.61
- PRME $5.66
- Analyst Decision
- LEGH Strong Buy
- PRME Buy
- Analyst Count
- LEGH 1
- PRME 6
- Target Price
- LEGH $29.00
- PRME $8.88
- AVG Volume (30 Days)
- LEGH 97.2K
- PRME 4.3M
- Earning Date
- LEGH 11-11-2025
- PRME 11-11-2025
- Dividend Yield
- LEGH N/A
- PRME N/A
- EPS Growth
- LEGH 2.38
- PRME N/A
- EPS
- LEGH 2.23
- PRME N/A
- Revenue
- LEGH $184,284,000.00
- PRME $4,961,000.00
- Revenue This Year
- LEGH $1.51
- PRME $179.58
- Revenue Next Year
- LEGH $7.92
- PRME N/A
- P/E Ratio
- LEGH $9.72
- PRME N/A
- Revenue Growth
- LEGH 8.79
- PRME 739.42
- 52 Week Low
- LEGH $20.85
- PRME $1.11
- 52 Week High
- LEGH $29.45
- PRME $6.94
- Technical
- Relative Strength Index (RSI)
- LEGH 19.15
- PRME 55.76
- Support Level
- LEGH $20.85
- PRME $5.66
- Resistance Level
- LEGH $27.59
- PRME $6.85
- Average True Range (ATR)
- LEGH 0.94
- PRME 0.56
- MACD
- LEGH -0.67
- PRME -0.04
- Stochastic Oscillator
- LEGH 11.00
- PRME 38.01
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.